The field of ophthalmology is undergoing a transformative change thanks to innovative retinal clinical trials. With the incidence rate of eye disorders, particularly retinal diseases, continuing to climb in populations worldwide, these trials are becoming the bedrock for new treatment modalities. This article aims to shed light on how retinal clinical trials are revolutionizing the way we approach and treat eye diseases.

Choosing the right Clinical Research Organization (CRO) is a critical decision for any pharmaceutical company. The selected CRO can significantly impact the success of your clinical trials and, ultimately, the time-to-market for your drug candidates. But with a sea of options, what should you focus on when evaluating a CRO? Here are key considerations to ensure you make the best choice:

Clinical research is a significant element of healthcare development, and the field of ophthalmology, specifically retinal disorders, is no exception. With the proliferation of ground-breaking research into retinal diseases like age-related macular degeneration (AMD), geographic atrophy, diabetic macular edema, and inherited retinal disorders, the need for expertise in this complex arena is ever-growing. That’s where we, as a retina-specialized Clinical Research Organization (CRO), enter the picture. At InFocus Clinical, we believe our specialized services provide a critical advantage in clinical trials for retinal diseases.